Get the Stockscreener App
9.80
4.70%
0.44
Pre-market:
9.53
-0.27
-2.76%
Stoke Therapeutics Inc stock is traded at $9.80, with a volume of 737.79K.
It is up +4.70% in the last 24 hours and down -16.10% over the past month.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
See More
Previous Close:
$9.36
Open:
$9.47
24h Volume:
737.79K
Relative Volume:
1.27
Market Cap:
$519.08M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-4.135
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
+12.90%
1M Performance:
-16.10%
6M Performance:
-27.84%
1Y Performance:
+98.78%
1-Day Range:
$9.30
$9.815
1-Week Range:
$8.8113
$9.815
52-Week Range:
$4.09
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.80 | 519.08M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat
Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register
Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register
Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat
What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World
Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada
Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat
Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks
STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stoke Therapeutics aligns with regulators on Dravet study - Investing.com
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Stoke Therapeutics Advances First Disease-Modifying Dravet Syndrome Treatment to Phase 3 - StockTitan
Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat
When (STOK) Moves Investors should Listen - Stock Traders Daily
Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow - Yahoo Finance
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street Corp - Defense World
State Street Corp Grows Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – What’s Next? - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth - Yahoo Finance
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):